Bucillamine in Treatment of Patients With COVID-19
Status:
Enrolling by invitation
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
This is a Phase 3, multi-center, randomized, double blind, placebo controlled, clinical study
of bucillamine (2 dosage levels) in patients with mild-moderate COVID-19. Patients will be
randomized 1:1:1 to receive bucillamine 100 mg 3 times a day (TID), bucillamine 200 mg TID or
placebo TID for up to 14 days. After the first interim analysis when a single dose is
selected, patients will then be randomized 2:1 to the selected bucillamine dose or placebo
The study will be overseen by an independent Data and Safety Monitoring Board (DSMB). Up to
10 centers in the United States will conduct this study. Up to 1000 patients will be enrolled
in this study. Patients will participate in the study approximately 45 days.